Education
About Us
Working with TipRanks
Follow Us
Arecor Therapeutics PLC (GB:AREC)
LSE:AREC
Total Valuation
Arecor Therapeutics PLC has a market cap or net worth of £31.72M. The enterprise value is 14.71M.
Market Cap£31.72M
Enterprise Value14.71M
Share Statistics
Arecor Therapeutics PLC has 37,756,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding37,756,600
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Arecor Therapeutics PLC’s return on equity (ROE) is -1.91 and return on invested capital (ROIC) is -180.66%.
Return on Equity (ROE)-1.91
Return on Assets (ROA)-1.17
Return on Invested Capital (ROIC)-180.66%
Return on Capital Employed (ROCE)-1.96
Revenue Per Employee101.06K
Profits Per Employee-212.36K
Employee Count50
Asset Turnover0.58
Inventory Turnover7.34
Valuation Ratios
The current PE Ratio of Arecor Therapeutics PLC is ―. Arecor Therapeutics PLC’s PEG ratio is -0.22.
PE Ratio―
PS Ratio4.86
PB Ratio4.59
Price to Fair Value4.59
Price to FCF-2.68
Price to Operating Cash Flow-5.36
PEG Ratio-0.22
Income Statement
In the last 12 months, Arecor Therapeutics PLC had revenue of 5.05M and earned -10.24M in profits. Earnings per share was -0.33.
Revenue5.05M
Gross Profit1.54M
Operating Income-10.70M
Pretax Income-10.62M
Net Income-10.24M
EBITDA-10.15M
Earnings Per Share (EPS)-0.33
Cash Flow
In the last 12 months, operating cash flow was -6.09M and capital expenditures -106.00K, giving a free cash flow of -6.20M billion.
Operating Cash Flow-6.09M
Free Cash Flow-6.20M
Free Cash Flow per Share-0.16
Dividends & Yields
Arecor Therapeutics PLC pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.95
52-Week Price Change14.81%
50-Day Moving Average69.04
200-Day Moving Average54.17
Relative Strength Index (RSI)53.41
Average Volume (3m)83.61K
Important Dates
Arecor Therapeutics PLC upcoming earnings date is Apr 28, 2026, Before Open (Confirmed).
Last Earnings DateSep 25, 2025
Next Earnings DateApr 28, 2026
Ex-Dividend Date―
Financial Position
Arecor Therapeutics PLC as a current ratio of 2.53, with Debt / Equity ratio of 6.06%
Current Ratio2.53
Quick Ratio2.38
Debt to Market Cap<0.01
Net Debt to EBITDA0.30
Interest Coverage Ratio-486.23
Taxes
In the past 12 months, Arecor Therapeutics PLC has paid -382.00K in taxes.
Income Tax-382.00K
Effective Tax Rate0.04
Enterprise Valuation
Arecor Therapeutics PLC EV to EBITDA ratio is -2.13, with an EV/FCF ratio of -2.35.
EV to Sales4.27
EV to EBITDA-2.13
EV to Free Cash Flow-2.35
EV to Operating Cash Flow-2.36
Balance Sheet
Arecor Therapeutics PLC has £1.89M in cash and marketable securities with £173.00K in debt, giving a net cash position of £1.71M billion.
Cash & Marketable Securities£1.89M
Total Debt£173.00K
Net Cash£1.71M
Net Cash Per Share£0.05
Tangible Book Value Per Share£0.16
Margins
Gross margin is -6.80%, with operating margin of -211.70%, and net profit margin of -202.57%.
Gross Margin-6.80%
Operating Margin-211.70%
Pretax Margin-210.13%
Net Profit Margin-202.57%
EBITDA Margin-200.87%
EBIT Margin-209.70%
Analyst Forecast
The average price target for Arecor Therapeutics PLC is £68.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target£68.00
Price Target Upside-19.05% Downside
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast3.31%
EPS Growth Forecast21.91%